Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Zyomyx receives $7.5m from UNITAID to commercialize MyT4 CD4 test

Zyomyx has received $7.5m from UNITAID, hosted and administered by the World Health Organization, for commercializing the company’s MyT4 point-of-care CD4 test.

Zyomyx has developed the MyT4 point-of-care CD4 test to guide HIV/AIDS treatment initiation and monitoring in low- and middle-income countries. The quantitative diagnostic will support expanded access to HIV treatment.

The company claims that MyT4 CD4 test is the fastest point-of-care CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry. The test, which obtained CE Mark approval in December 2013, gives results in ten minutes from a finger-prick sample.

It does not have complex instrumentation and requires no maintenance or swap to a central location for repairs.

Zyomyx president and CEO Peter Wagner noted that the company is fully aligned with UNITAID’s approach to address public health issues as well as the market conditions to bring diagnostic technology to those most in need.

"UNITAID’s innovative use of financing and market power to effect change makes it a transformational player in the global health arena," Wagner added.